Histoplasmosis Treatment Top Companies-Recent Developments, Business Strategy, Deal Strategy, Patent Strategy, Benchmarking and Management Outlook

Histoplasmosis Treatment Market Size Analysis and Top Companies

The global histoplasmosis treatment market size is estimated to hit around USD 4.94 billion by 2033, increasing from USD 2.08 billion in 2023 with a CAGR of 9.25% from 2023 to 2033.The top companies operating in the histoplasmosis treatment market are Alembic Limited, Sun Pharmaceutical Industries Ltd., Novartis AG, Merck & Co., Inc., Pfizer Inc., Hindustan Antibiotics Limited, Siemens Healthcare GmbH, Sanofi-Aventis Groupe, and Others.

Market Report Coverage

Histoplasmosis Treatment Key Players

• Alembic Limited
• Sun Pharmaceutical Industries Ltd.
• Novartis AG
• Merck & Co., Inc.
• Pfizer Inc.
• Hindustan Antibiotics Limited
• Siemens Healthcare GmbH
• Sanofi-Aventis Groupe

Recent Developments 

• In August 2023, CVS Health announced the launch of Cordavis. This wholly owned subsidiary will collaborate directly with manufacturers to co-produce and/or commercialize biosimilar medicines for the US pharmaceutical market. The FDA-approved Cordavis drugs will be of excellent quality, simple for patients to use, and contribute to a steady, long-term supply of reasonably priced biosimilars. 
• In June 2022, in order to successfully control fungal infections, Apex Laboratories Pvt Ltd introduced an enhanced type of Itraconazole Capsules Supra Bioavailable in dosages of 65 and 130 mg.

We have prepared a service to support you. please feel free to contact us at sales@precedenceresearch.com | +1 804 441 9344